Active Grant Support

  • Title: Molecular Epidemiology of NHL and CLL

    Grant Number: R01 CA92153-7
    Principal Investigator: James R. Cerhan, M.D., Ph.D.
    Funded By: National Institutes of Health / National Cancer Institute
    Grant Duration: 09/26/08 – 07/31/13
    Role: Principal Investigator
    Description: Case-control study to identify environmental and genetic risk factors for NHL and CLL.
  • Title: Molecular Epidemiology of NHL and CLL (Supplement 1)

    Grant Number: R01 CA92153-7S1
    Principal Investigator: James R. Cerhan, M.D., Ph.D.
    Funded By: National Institutes of Health / National Cancer Institute
    Grant Duration: 09/30/09 – 09/29/11
    Role: Principal Investigator
    Description: Supplement to develop a Data Coordinating Center to facilitate pooling of InterLymph studies, in order to accelerate scientific progress in uncovering genetic, environmental, and gene-environment interactions in the etiology of NHL.
  • Title: Molecular Epidemiology of Non-Hodgkin Lymphoma Survival

    Grant Number: R01 CA129539-1
    Principal Investigator: James R. Cerhan, M.D., Ph.D.
    Funded By: National Institutes of Health / National Cancer Institute
    Grant Duration: 07/17/09 – 06/30/11
    Role: Principal Investigator
    Description: Prognostic cohort study to identify host genetic, tumor, and lifestyle factors that predict survival from diffuse large B-cell and follicular lymphoma.
  • Title: Lymphoma Specialized Program of Research Excellence (SPORE). Project 3: Biology and Epidemiology of APRIL and BLyS in B-Cell NHL

    Grant Number: P50 CA97274-8
    Principal Investigator: Thomas E. Witzig, M.D.
    Project 3 Principal Investigator: James R. Cerhan, M.D., Ph.D.
    Funded By: National Institutes of Health / National Cancer Institute
    Grant Duration: 07/01/07 – 06/30/12
    Role: Project Leader
    Description: SPORE Project to determine if genetic variability in BLyS, APRIL and their receptors TACI, BCMA, and BAFFR, are associated with the etiology and prognosis of NHL and selected NHL subtypes. In addition to genetic studies, we also propose to determine the role of APRIL on the biology of NHL B cells.
  • Title: Biology and Epidemiology of BLyS and APRIL in Follicular Lymphoma

    Grant Number: FDNT-2
    Principal Investigator: Anne Novak, Ph.D.
    Funded By: Lymphoma Research Foundation
    Grant Duration: 06/01/07 – 05/31/10
    Role: Co-Investigator
    Description: Study to determine if genetic variability in BLyS, BLyS receptors, and the BLyS-related TNF molecule APRIL are associated with the development of follicular lymphoma and the clinical outcomes of patients.
  • Title: Epidemiology of Cancer in a Cohort of Older Women

    Grant Number: R01 CA39742-8
    Principal Investigator: Aaron R. Folsom, M.D., M.P.H.
    Subcontract Principal Investigator: James R. Cerhan, M.D., Ph.D.
    Funded By: National Institutes of Health / National Cancer Institute
    Grant Duration: 03/01/05 – 01/31/10
    Role: Subcontract Principal Investigator
    Description: Subcontract from University of Minnesota for conduct of the Iowa Women's Health Study, a prospective cohort study of the determinants of cancer in 41,837 Iowa women originally enrolled in 1986.
  • Title: Genetic Epidemiology of Chronic Lymphocytic Leukemia

    Grant Number: U01 CA118444-4
    Co-Investigator: Susan L. Slager, Ph.D.
    Co-Investigator: James R. Cerhan, M.D., Ph.D.
    Funded By: National Cancer Institute
    Grant Duration: 08/23/06 – 08/22/11
    Role: Co-Investigator
    Description: A multicenter consortium to collect CLL families, including unaffected first degree relatives of CLL cases to determine MBL status and to perform a genome-wide linkage study to identify novel susceptibility genes.
  • Title: Predictors of Adult Leukemia

    Grant Number: R01 CA107143-5
    Principal Investigator: Julie A. Ross, Ph.D.
    Subcontract Principal Investigator: James R. Cerhan, M.D., Ph.D.
    Funded By: National Cancer Institute
    Grant Duration: 04/01/05 – 02/28/10
    Role: Subcontract Principal Investigator
    Description: Population-based case-control study to identify genetic and environmental risk factors for adult leukemia.
  • Title: Mayo Comprehensive Cancer Center Grant--Program Leadership

    Grant Number: P30 CA15083-35
    Principal Investigator: Robert B. Diasio, M.D.
    Funded By: National Institutes of Health / National Cancer Institute
    Grant Duration: 04/17/09 – 02/28/14
    Role: Program Leader
    Description: The purpose of the CCSG is to provide infrastructure support for the Mayo Clinic Cancer Center. Effort for Dr. Cerhan is for his role as Leader of the Genetic Epidemiology and Risk Assessment Program.
  • Title: Mayo Clinic Center for Clinical and Translation Research – Research Mentor: H. Chakkera

    Grant Number: UL1 RR 24150-3
    Co-Investigator: Robert A. Rizza, M.D.
    Funded By: National Institutes of Health / National Center for Research Resources
    Grant Duration: 07/30/08 – 06/30/10
    Role: Mentor
    Description: Dr. Cerhan serves as the primary mentor of the KL2 Career Development Award for Dr. Harini Chakkera. Her main project is entitled "Predictive model for post transplant diabetes mellitus after renal transplantation."
  • Title: Genetic Epidemiology of Cell Division Regulation in Breast Cancer

    Grant Number: R01 CA122340-2
    Principal Investigator: Fergus J. Couch, Ph.D.
    Funded By: National Institutes of Health / National Cancer Institute
    Grant Duration: 06/01/07 – 04/30/12
    Role: Co-Investigator
    Description: Case-control study of the role of inherited genetic variants in genes that are critical to regulating cell division in the etiology of breast cancer.
  • Title: DNA Damage-Response Defects in Prostate Cancer Risk

    Grant Number: R01 CA115555-2
    Principal Investigator: Wanguo Liu, Ph.D.
    Subcontract Principal Investigator: Stephen N. Thibodeau, Ph.D.
    Funded By: National Institutes of Health / National Cancer Institute
    Grant Duration: 04/29/08 – 07/31/12
    Role: Co-Investigator
    Description: The goal of this study is to identify novel variants in DNA damage response genes and evaluate these as susceptibility loci in a prostate cancer case-control study.